EKF Diagnostics (LON:EKF) Insider Purchases £19,550 in Stock

EKF Diagnostics Holdings plc (LON:EKF) insider Julian Baines acquired 85,000 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average price of GBX 23 per share, for a total transaction of £19,550.

EKF Diagnostics Price Performance

EKF Diagnostics stock opened at GBX 25.30 on Friday. The stock has a market cap of £110.15 million, a price-to-earnings ratio of 18.74 and a beta of 0.57. The company has a quick ratio of 1.77, a current ratio of 4.60 and a debt-to-equity ratio of 0.34. The business has a 50-day simple moving average of GBX 25.58 and a 200 day simple moving average of GBX 27.26. EKF Diagnostics Holdings plc has a 52 week low of GBX 18.40 and a 52 week high of GBX 32.

EKF Diagnostics (LON:EKF) last released its quarterly earnings results on Tuesday, September 16th. The company reported GBX 0.43 earnings per share for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. On average, research analysts forecast that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.